Related Experiment Videos
Hepatitis C virus infection: co-infection with HIV and HBV
1Department of Medicine, Imperial College School of Medicine at St Mary's Hospital, London, UK.
Insights
Hepatitis C virus (HCV) co-infection with HIV or HBV accelerates liver disease. Improved HIV treatments reveal HCV
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) shares transmission routes with hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
- HCV co-infection with HBV or HIV is increasingly recognized, particularly with improved HIV survival rates.
- Previously, HIV-related mortality overshadowed HCV's impact on liver disease progression.
Purpose of the Study:
- To investigate the impact of HIV and HBV co-infection on Hepatitis C progression.
- To understand the interaction between these viruses and their effect on liver disease.
- To inform optimal management strategies for co-infected patients.
Main Methods:
- Observational studies comparing disease progression in mono-infected vs. co-infected patients.
- Analysis of liver disease markers and fibrosis rates in co-infected individuals.
- Review of current and emerging treatment approaches for viral hepatitis co-infections.
Main Results:
- HIV co-infection, especially with controlled HIV, leads to earlier onset of advanced liver disease in HCV patients.
- HBV co-infection exacerbates HCV-related liver disease, increasing hepatic fibrosis.
- The precise mechanisms of viral interaction in co-infection are not fully understood.
Conclusions:
- Hepatitis C co-infection with HIV or HBV significantly worsens liver disease outcomes.
- Combination antiviral therapy is likely necessary for managing these complex co-infections.
- Further research is needed to define optimal treatment protocols for HCV/HIV and HCV/HBV patients.
Abstract:
Hepatitis C shares common routes of infection with hepatitis B (HBV) and the human immunodeficiency virus (HIV). It is, therefore, not surprising to find that some patients with HCV are co-infected with either HIV and/or HBV. Until recently, the effects of HIV on HCV infection have not been investigated--sadly patients with HIV died long before their liver disease became problematic. However, the development of successful therapies for HIV have led to dramatic improvements in life expectancy for patients infected with this virus and in these patients, with well controlled HIV, it is becoming clear that hepatitis C may lead to the early onset of advanced liver disease. The optimal treatment for these patients is unknown but it seems likely that combination antiviral therapy will be required. The effects of HBV on HCV are also beginning to be investigated and, again, it is clear that co-infection leads to more aggressive liver disease with the two viruses interacting in poorly defined ways to increase the rate of hepatic fibrosis. Management of combined HCV/HBV infection is still under investigation and will probably involve combination therapy.